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Abstract
Background: Over the last ten years, miniaturized multiplexed immunoassays have become robust, reliable research tools
that enable researchers to simultaneously determine a multitude of parameters. Among the numerous analytical protein
arrays available, bead-based assay systems have evolved into a key technology that enables the quantitative protein
profiling of biological samples whilst requiring only a minimal amount of sample material.
Methodology/Principal Findings: A microfluidic bead-based immunoassay, mFBI, was developed to perform bead-based
multiplexed sandwich immunoassays in a capillary. This setup allows the simultaneous detection of several parameters and
only requires 200 ng of tissue lysate in a 1 mL assay volume. In addition, only 1 mL of detection antibodies and 1 mL of the
reporter molecule Streptavidin-Phycoerythrin were required. The mFBI was used to compare the expression of seven
receptor tyrosine kinases and their degree of tyrosine phosphorylation in breast cancer tissue and in normal tissue lysates.
The total amount of HER-2, as well the degree of tyrosine phosphorylation was much higher in breast cancer tissue than in
normal tissue. mFBI and a standard bead-based assay led to identical protein expression data. Moreover, it was possible to
reduce the quantity of sample material required by a factor of 100 and the quantity of reagents by a factor of 30.
Conclusions/Significance: The mFBI, microfluidic bead-based immunoassay, allows the analysis of multiple parameters from
a very small amount of sample material, such as tumor biopsies or tissue sections.
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Introduction
Over the last ten years, protein microarray technologies have
progressed to become effective multiplex analysis tools for assessing
the expression and function of proteins from a small amount of
sample material [1–6]. Microarrays are solid phase-based assay
systems consisting of an array of miniaturized test sites, in which
many tests can be performed in parallel. Planar protein microarrays
use capture molecules that are immobilized in microspots of rows
and columns, making it possible to analyze a large number of
parameters simultaneously [7–10]. In analogy to the spatial
separation employed by planar microarrays, bead-based systems
employ color-coded or size-coded microspheres to identify different
immunoassays. Different color-coded microspheres are coated with
different capture antibodies and incubated with the samples of
interest. A secondary detection antibody and a reporter molecule
are used to visualize the captured analytes. The individual bead
types are identified in a flow cytometer and the number of bead-
captured analytes is determined. Bead-based systems have emerged
as very interesting alternatives to planar microarrays, especially in
focused analyses where the number of parameters to be analyzed
simultaneously is relatively small and the number of samples to be
analyzed isquite high [11].Luminex’sxMAPtechnologyisthe most
advanced bead-based technology currently available; it involves a
flow cytometry system that can handle 96-well microtiter plates and
is equipped with advanced digital signal processing hardware and
software. Luminex microspheres are 5.6 mm in diameter and
stained with different proportions of a red and an infrared dye,
which results in 100 distinct color-coded beads. The beads enable
researchers to screen up to 100 parameters in a single experiment.
Such bead-based assay systems are flexible, robust, and, in contrast
to planar microarrays, more advanced in terms of automation [12].
There is a growing list of commercially available, ready-to-use,
multiplexed bead-based assays for the quantification of cytokines
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13125and cell-signaling molecules and the analysis of kinase activity
(www.biochipnet.de, Biochipnet).
The information obtained from multiplexed assays helps in the
detection of molecular events in the early stages of cancer
progression and in the early diagnosis of cancer. As early-stage
tumor sample size is usually small, therefore it is only possible to
obtain small amounts of material, for example, fine needle
aspiration [13–15]. The identification of changes in protein
expression in very small samples is especially challenging since only
a limited number of assays can be performed using conventional
approaches.It goes without sayingthat thepotential ofgenomic and
proteomic technologies can only be fully exploited if they can be
applied to minute amounts of biological material [16–19].
Multiplexed immunoassays based on protein microarray plat-
formshavebeenbroadlyemployedinthe discoveryand validation of
disease-associated biomarkers as well as in clinical diagnostics
research [20–25]. However, there is still a great need for integrated
microfluidic test devices which would ideally perform multiplexed
immunoassays in a controlled environment whilst using only small
amounts of sample material, like fine needle biopsies or microdis-
sected tissue sections. The present study presents a microfluidic,
bead-based immunoassay (mFBI) approach for the multiplexed
detection of proteins involving a capillary to control the application
of minute amounts of liquid. Performing an immunoassay inside a
capillary requires only 200 ng tissue lysate present in 1 mLs a m p l e
volume, 1 mL detection antibody solution and 1 mL of reporter
molecule streptavidin-phycoerythrin. This corresponds to a 100-fold
and 30-fold reduction in sample and reagents compared to standard
bead-based immunoassays. The present paper describes the setup of
the microfluidic bead-based immunoassay and demonstrates the
performance of the mFBI by analyzing the expression of receptor
tyrosine kinases in lysates from breast cancer and normal tissue.
Results and Discussion
Multiplexed immunoassay can be performed in a capillary
requiring only a minute amount of sample material. Phillips et al.
(2007) analyzed the expression of twelve cytokines in dissected
tissue lysates. The cytokines were captured by a mixture of
immobilized capture antibodies, and subsequently labeled with a
flurophore. Captured and labeled cytokines were separated by
electrophoresis and the quantification of individual cytokine peaks
was performed [26–28]. For this approach high quality capture
antibodies are required revealing high-affinity and high-specificity
[27]. O’Neill et al. reported a high-resolution capillary isoelectric
focusing technology which resolved isoforms and individual
phosphorylation forms of target analytes. The separated proteins
and their isoforms were immobilized by a photochemical capture
method in the capillary, and subsequently visualized with specific
antibodies using a chemiluminescence based readout [29–30].
Good sensitivity and resolution of protein isoforms could be
achieved with this method. However, the ability of multiplexing of
this approach is limited and only a few numbers of analytes can be
analyzed simultaneously. As an alternative approach, we applied
multiplexed sandwich immunoassay technology and performed a
micro fluidic bead-based immunoassay –mFBI – in a capillary.
Optimization of relevant parameters for microfluidic
bead-based immunoassay – mFBI
The schematic set up for mFBI is shown in Figure 1A. It consists
of a syringe pump, a syringe, an incubation zone and two
capillaries. The incubation zone is comprised of a filter and an
adapter to connect two capillaries at both sides. The left capillary
is connected to the syringe pump and the right capillary is
connected to the sample solution reservoir (Figure 1B). The mFBI
can be performed by controlling the solution flow in and out of the
capillary with the syringe pump.
The relevant parameters of the mFBI were optimized using an
artificial capture assay consisting of an immobilized anti-biotin
antibody and biotinylated PE as the analyte. The optimal number
of antibody coupled beads was defined in a first experiment. 250,
500, 1000, or 2000 beads were pumped into the capillary and
incubated for 5 min with Biotin-PE (100 ng/ml). The median
fluorescent intensity (MFI) and the number of recovered beads
were analyzed (Figure 2A). The MFI value reflects the amount of
captured Biotin-PE and the number of recovered beads correlates
to the robustness of the MFI signal. At least 35 recovered beads
Figure 1. Schematic illustration of microfluidic bead-based immunoassay (mFBI). (A) The assay is performed in a capillary by controlling the
solution flow into or out of the capillary with a syringe pump. A filter (pore diameter=0.5 mm) is used to keep the antibody-coated beads at the
incubation site to capture target analytes and to react with detection reagents. After incubation, the beads are pumped out and submitted to a
Luminex 100 IS instrument for fluorescent signal readout. (B) The structure of the incubation zone consists of a filter and an adaptor to connect two
fused silica-capillaries at both sides. The left capillary is connected to a syringe pump and the right capillary is connected to a sample solution
reservoir.
doi:10.1371/journal.pone.0013125.g001
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requirements for the use of median signals. The number of
recovered beads increased with an increasing starting amount of
beads. Using 1000 and 2000 beads in the assay more than 50
beads were counted resulting in a robust MFI signal. Therefore,
1000 beads for each bead type were used in further experiments.
Next, the influence of the coating surface of capillary was
investigated. Capillaries with four different physical surface
properties (untreated, phenyl-silicon, polyethylene glycol and
polyacrylamid) were tested for their performance of the mFBI
assay (Figure 2B). The highest MFI values and a sufficient number
of recovered beads above 50 was obtained using the capillary with
a hydrophobic phenyl-silicon coating surface. This might be due to
the very low flow rate, which may not transport all the beads
through the capillary.
Thirdly, the optimal assay volume (0.5, 1, 2, 4, 8 and 16 ml) was
determined using the Streptavidin - Biotin-PE assay. 1000 anti-
biotin antibody coated beads were incubated with Biotin-PE
(100 ng/ml) for 5 min by changing the flow rate from 0.1, 0.2, 0.4,
0.8, 1.6 up to 3.2 ml/min. The generated MFI and the number of
recovered beads are given in Figure 2C. The data revealed that
the MFI value was enhanced steadily when sample volume was
increased from 0.5 to 16 ml. However, the number of recovered
beads decreased below 50 when the volume exceeded 4 ml and the
flow rate was above 0.8 ml/min, respectively.
The optimal incubation time was determined using the
Streptavidin - Biotin-PE assay. The different incubation periods
(1, 5, 30, 60 and 120 min) of the anti-biotin antibody coated beads
with 1 mL Biotin-PE (100 ng/ml) were achieved by adjusting the
flow rate from 1 ml/min, down to 0.008 ml/min. The results
revealed that the MFI value increased with longer incubation
times whereas the number of recovered beads decreased below 50
when the incubation time was extended above 60 min (Figure 2D).
These data revealed that high flow rates result in shorter
incubation times but with the downside of a poor bead recovery.
An increase in sensitivity of the mFBI could be achieved using
larger sample volumes while keeping the incubation time constant
(Figure 2C), or increase the incubation time while keeping the
sample volume constant (Figure 2D).
Finally, the performance of mFBI assay was evaluated by the
quantitative analysis of different biotin-PE concentrations. Anti-
biotin antibody coated beads were incubated with 1 ml of Biotin-
PE using concentrations ranging from 0 to 5000 ng/ml for 5 min,
respectively. As a negative control BSA coated beads of a
differently color-coded bead type were used in the same assay.
The data are shown in Figure 3. At the lowest Biotin-PE
concentration of 0.32 ng/ml, the MFI of signal to background was
still 14/3. The dynamic range of the assay was from 0.32 to
500 ng/ml. Unspecific signals observed on the BSA coated beads
increased slightly at Biotin-PE concentrations above 100 ng/ml.
Figure 2. Optimization of mFBI-relevant parameters. (A – D) denote the optimization of bead number, capillary coating surface, analyte
volume, and incubation time, respectively. In the experiment, anti-biotin antibody-coated beads were incubated in the capillary with biotin-PE
(100 ng/ml). The resulting beads were then pumped out and diluted in 100 mL with assay diluent and analyzed with the Luminex 100 IS system using
fluorescent detection. The numbers in gray given in C and D represent the flow rate of the sample solution. The MFI value (column for A and B, circle
for C and D) was read out and the recovered beads (square) were counted with the Luminex 100 IS system.
doi:10.1371/journal.pone.0013125.g002
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(1000), the surface coating (phenyl-silicon), the analyte volume
(1 mL), incubation time (60 min) and quantitation ability of the
mFBI assay. In a next step, the mFBI was applied to the analysis of
Receptor Tyrosine Kinases in tissue lysates.
Multiplexed detection of seven Receptor Tyrosine
Kinases in breast cancer tissue
A commercially available bead-based sandwich immunoassay -
WideScreenTM Receptor Tyrosine Kinase Assay (RTK) Kit - was
selected to evaluate the performance of the mFBI. RTKs are
critical regulators of numerous cell signaling pathways. Ligand
binding to the extracellular domain of transmembrane RTKs
triggers receptor dimerization and autophosphorylation of an
intracellular kinase domain. This event ultimately triggers
activation of downstream pathway proteins via phosphotyrosine-
SH2 domain interactions. RTKs have been shown to be not only
key regulators of normal cellular processes but also to have a
critical role in the development and progression of many types of
cancer [31–33]. For seven RTKs - Epidermal Growth Factor
Receptor (EGFR), Insulin-like Growth Factor 1 Receptor (IGF-
1R), Hepatocyte Growth Factor Receptor (HGFR), Platelet-
Derived Growth Factor Receptor beta (PDGFRb), Human
Epidermal Growth Factor Receptor 2 (HER-2), Vascular
Endothelial Growth Factor Receptor 2 (VEGFR2) and Tyrosine
Kinase with Immunoglobulin and EGF Repeats 2 (Tie-2) - the
total amount and the phosphorylation levels were measured in a
breast cancer and a normal tissue lysate using the standard bead-
based sandwich immunoassay protocol and the mFBI.
Considering the relationship between the assay sensitivity and
incubation time as well as influence of flow rate (Figure 2D), the
capture antibody coated beads were incubated for 60 min with
the tissue lysates, for 60 min with biotinylated detection antibody
mix and subsequently for 45 min with the reporter molecule
Streptavidin-PE (each 1 mL). In parallel, a standard bead-based
assay was performed according to the manufacturer’s instruc-
tion. Signal intensities representing the RTK concentrations
(Fig. 4A, C) and their degree in Tyrosine phosphorylation
(Fig. 4B, D) correlated very well between the mFBI and the
standard bead-based assay. No significant differences of the
fluorescent intensities of the different analytes between both
methods were observed (Figure 4). Both methods revealed for
HER-2 that both the total amount and the degree of Tyrosine
phosphorylation were significantly higher in breast cancer tissue
compared to normal tissue. However, the mFBI only required
200 ng of tissue lysates, compared to 20 mg in the standard bead-
based assay. For the detection antibody mix and the reporter
solution Streptavidin-PE the mFBI required 30-fold less material
(Table 1).
Multiplexing of beads in the mFBI is not limited due to the very
low sample volume of only 1 mL. In such a volume 100 different
bead types can be incubated simultaneously and subsequently
analyzed in a Luminex instrument. A set of 100 different bead
types were incubated into the capillary for 1 h mimicking real
incubation conditions. After this incubation time beads were
pumped out of the capillary and counted in a Luminex 100
instrument. For each bead type a sufficient number of beads above
35 were counted which are sufficient to fulfill statistical
requirements, when measuring MFIs (Figure 5).
Several aspects have to be considered to perform a successful
mFBI experiment. Firstly, bubbles in the capillary have to be
avoided, as bubbles severely influence the accuracy of bead
numbers or sample volume during the assay. According to our
experience, this problem could be significantly minimized by
tightly sealing the connection between the microfilter and capillary
and a carefully operation. In addition the dead volume of beads or
sample has to be controlled. In our experiment, the capillaries
were washed thoroughly with washing buffer in between
consecutive assay runs. After extensive washing no residual beads
could be observed, which allowed us to reuse the setup. In the here
presented experimental setup two capillaries were used allowing to
perform two assays in parallel. To increase sample throughput the
number of capillaries can be increased as described recently by
Bainer et al. [34]. Bainer et al. adapted a CE based separation of
Figure 3. Quantification of Biotin-Phycoerythrin using the mFBI assay. 1,000 anti-biotin antibody-coated beads were incubated with
different concentrations of biotin-phycoerythrin (1 ml) for 5 min, respectively. A BSA-coated bead served as a control. The MFI generated with the
anti-biotin antibody (triangle) or the BSA-coated beads (circle) are shown.
doi:10.1371/journal.pone.0013125.g003
mFluidic Immunoassay
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13125proteins to the microtiter plate format and used 96 capillaries in
parallel. The integration of a flow cytometry based read-out
system in such a set up could extend the mFBI concept to a
compact and automatable system which would allow to process
large number of samples in parallel and simultaneously screen for
several dozens of analytes in a single experiment [35].
Figure 4. Protein expression analysis using the mFBI. Total protein expression and phosphotyrosine-specific expression of seven RTKs were
determined by mFBI (A and B) and a normal bead-based assay (C and D). For mFBI, seven mixed capture antibody-coated beads (1,000 beads per
analyte) were incubated with tissue lysates (1 ml) for 60 min, mixed biotinylated detection antibodies (1 ml) for 60 min and Strep-PE (1 ml) for 45 min.
The MFI value was obtained with a Luminex 100 IS system.
doi:10.1371/journal.pone.0013125.g004
Table 1. Comparison of mFBI and standard bead-based assay.
Procedure Micro fluidic bead-based assay Standard bead-based assay Fold reduction
Time Usage per capillary Time Usage per well
Pre-wet 10 min 20 mL 5 min 100 mL
Beads 1 mL, 1000beads/analyte 30 mL, 2000beads/analyte
Vacuum - -
Sample 60 min 1 mL, 200 ug/ml 60 min 100 mL, 200 ug/ml 1006
36wash - -
Detection antibody 60 min 1 mL, 16 60 min 30 mL, 16 306
36wash - -
Strep-PE 60 min 1 mL, 16 60 min 30 mL, 16 306
36wash - -
Recover beads 3 min 5 mL- -
Measurement 80 mL, 80 s, Gate: 7500–15000 80 mL, 80 s, Gate: 7500–15000
-: without this procedure.
doi:10.1371/journal.pone.0013125.t001
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Beads coupling
2.5610
6 carboxylated colour coded beads with an diameter of
5.6 mm were obtained from Luminex, Inc. (Austin, TX, USA), and
were coupled with 25 mg (100 mg/ml) Bovine serum albumin
(BSA, Sigma, Inc., MO, USA)) or 25 mg (100 mg/ml) anti-biotin
antibody (Sigma, Inc., MO, USA) according to the manufacturer’s
protocol. The coupled beads were stored at 4uC in Roche buffer
(Roche Diagnostics GmbH, Mannheim, Germany) with 0.05%
sodium azide. Coupling controls were used to assess the
immobilization efficiency by staining 1500 of each type of
microspheres with 0, 0.1, 0.3, 1 and 3 ug/ml R-phycoerythrin
conjugated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories, Inc., Suffolk, UK).
mFBI setup
The mFBI set up consists of a syringe pump, incubation zone
and two capillaries (Figure 1A). The KDS 200 syringe pump (KD
Scientific, Inc., Holliston, MA, USA) holds two syringes (25 mL,
Model 702, Innovative Labor Systeme GmbH, Stu ¨tzerbach,
Germany) which can perform the assay in duplicate. The
incubation zone consists of a microfilter (M-520, 0.5 mm porosity,
PEEK, IDEX Health & Science, Wertheim-Mondfeld, Germany)
and an adapter (Upchurch Scientific Oak Harbor, WA, USA) to
connect two fused silica-capillaries (Chromatographie Service
GmbH, Berlin, Germany). The left capillary (diameter=200 mm)
is connected to a syringe and the right capillary (diame-
ter=100 mm) is connected to a sample solution (Figure 1B).
Microfluidic bead-based assay
The WideScreen
TM Receptor Tyrosine Kinase Assay Kit was
obtained from EMD Chemicals Inc. (Gibbstown, NJ, USA). This
kit enables the quantification of a set of key RTKs, including
EGFR, IGFR, HGFR, PDGFRb, HER-2, VEGFR2, and Tie-2.
Breast cancer tissue and normal tissue were kindly provided by
Georg Sauer and Helmut Deissler, University hospital Ulm, Ulm
Germany [20]. Prior to the breast biopsies, an informed consent
was obtained in a written format (under approved internal review
board protocol 130/2003; University of Ulm). Lysates of breast
cancer tissue and normal tissue were prepared and diluted to
200 mg/ml with assay diluent according to the manufacturer’s
instructions.
Before starting the assay, the capillaries and pumps were rinsed
thoroughly to remove any remaining sample or beads with 20 mL
70% isopropanol (Roth, Karlsruhe, Germany). 1 mL diluted
antibody-coupled beads, 1,000 for each analyte, were pumped
into each capillary at a flow rate of 0.2 ml/min. The prepared
tissue lysates (200 mg/ml) were then pumped into the capillary and
incubated with the mixed antibody-coupled beads for 1 h at a flow
rate of 0.016 mL/min. Subsequently, the mixed biotinylated
detection antibodies (1X, provided in the kit) and Strepavidin-
Phycoerythrin (1X, provided in the kit) were pumped into the
capillary and incubated with the analytes captured on the beads
for 1 h and 45 min, respectively. After the assay was finished, the
beads were pumped out of the capillary in a volume of 5 mL and
diluted into 100 mL with assay diluent (1X). Finally, the diluted
beads were transferred into a 96-well ELISA microplate (Greiner
bio-one Ltd., Frickenhausen, Germany). Followed by incubation
for 5 min on a thermomixer (Eppendorf Inc., Hamburg,
Germany) at 650 rpm to mix the beads in solution, the resulting
beads were submitted to a Luminex 100 IS system for fluorescent
signal readout (DD gate: 7,500–15,000; sample size: 80 mL; 100
events per bead region; timeout: 80 sec). The MFI value was
extracted to perform data analysis.
Normal bead-based assay
The assay was carried out according to the instructions given by
the manufacturer for the WideScreen
TM Receptor Tyrosine
Kinase Assay Kit with minor modifications. In short, the
MultiScreen HTS
TM 96-well filter plate (Millipore, Inc., Massa-
chusetts, USA) was pre-wetted with assay diluent for 5 min,
100 mL/well. Then, 50 ml diluted (1X) capture beads were
transferred to each well. After removing the excess solution by
filtration, 100 mL of the same tissue lysates (200 mg/ml) were
added to each well to incubate with the beads at 23uC for 1 h on a
thermomixer (650 rpm). Subsequently, the beads were washed 3
times with 100 mL washing buffer in each well. Then, 30 mL
mixed detection antibodies (1X), 60 mL assay diluent, 30 mL
streptavidin-phycoerythrin (1X), 60 mL assay diluent were trans-
Figure 5. Simulation of a 100-plex assay. 800 beads of each bead type were incubated in the capillary for 1 h. Beads were pumped out and
counted with a Luminex-100 instrument. (A) Counted beads of the 100 different color-coded bead types which can be spectrally distinguished by
their colour code. (B) number of counted beads for each bead type.
doi:10.1371/journal.pone.0013125.g005
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thermomixer at 650 rpm, respectively. Followed by 3 washing
steps, 120 mL assay diluent (1X) were transferred to each well and
incubated for 5 min on a thermomixer (650 rpm). After these
procedures, the beads were submitted to a Luminex 100 IS system
for fluorescent signal readout (DD gate: 7500–15000; sample size:
50 ml; 100 events per bead region; timeout: 80 sec).
The graphs were drawn with Excel 2003 (Microsoft Corp.
Redmond, Washington, USA) and origin 7.0 (OriginLab Corp.,
Northampton, MA USA). The data of figure 2C,D were fit using a
4-parameter logistic fit from origin 7.0. The data of figure 3 were
fit using 5-parameter non-linear fit from Xfit4.0 (ID Business
Solutions Ltd. Guildford, Surrey, UK).
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